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ABSTRACT
Objective: This study investigated early nursing interventions with the purpose to minimize cetuximab-induced acneiform
eruption. The most important side-effect of cetuximab is dermatologic toxicity, up to 90%. Dose-reduction or interruption
of cetuximab reduces severity of dermatologic toxicity, probably at the cost of reduced efficacy of the cancer therapy. Thus,
prevention or effective supportive care during treatment is important. The study evaluated if patient education could ensure
compliance of cancer treatment and effect of oral tetracycline on acneiform eruption, with the purpose to minimize severity of
dermatologic toxicity and reduce the use of tetracycline.
Methods: The design was a single group prospective interventional study. Gastro-intestinal (GI) cancer patients treated with
cetuximab between April 2009 and June 2011 were educated to start treatment with tetracycline 500 mg twice daily when
acneiform eruption occurred. Patient’s dermatologic toxicity were graded (by CTCAE) and registered by nurses.
Results: Sixty-three patients were evaluable. Patients started tetracycline when acneiform eruption occurred. It reduced severity
but not incidence of acneiform eruption, 10% of the patients never developed acneiform eruption and therefore never received
tetracycline.
Conclusions: Patient-education by a trained oncology nurse in the handling of cetuximab induced acneiform eruption is
manageable and effective and ensures a high number of patients carrying through treatment with a full dose of cetuximab.
Key Words: Nursing interventions, Skintoxicity, Cetuximab, Acneiform eruption, Rash, Dermatologic toxicity, Patient
education, Tetracycline, Guideline
1. INTRODUCTION
Gastro-intestinal (GI) cancer is one of the most common
causes of cancer-related death in the Western countries.[1]
Since publication of the pivotal BOND study,[2] cetuximab
has been part of the therapeutic arsenal in patients with
metastatic colorectal cancer (mCRC). Cetuximab was first
introduced in chemo-resistant mCRC, but was later approved
in all lines[3] in combination with chemotherapy. Recently
it was shown that cetuximab should only be administered in
patients with rat sarcoma (RAS) wild type tumours.[4]
Cetuximab is associated with dermatological toxicity that
affects up till 90% of the patients, which may affect com-
pliance with the cancer treatment.[5] If severe skin toxicity
is prevented or limited it might minimize the need for dose-
reduction, dose-delay or discontinuation and it is natural to
assume that an increased dose-intensity will optimize efficacy
of cetuximab.
Dermatologic toxicity includes acneiform eruption, hyper-
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pigmentation, xerotic skin, pruritus, skin fissures and nail
changes. Severe dermatologic toxicity is most often seen
during the first two months of therapy. Dermatologic tox-
icity is identified in the literature with different terms e.g.
rash, acne, acne-like skin rash, acneiform eruption. In this
paper we use the term acneiform eruption expressed by Baas
and colleagues.[5] The side effects of cetuximab differ from
chemotherapy induced toxicity and therefore needs special
attention. In general, it is assumed that severe dermatologic
toxicity reduces patients’ quality of life.
Since the first randomized study was presented,[6] we have
offered oral tetracycline as part of our treatment strategy
for acneiform eruption. Scope et al. showed in a random-
ized controlled trial (n = 48) that prophylactic minocycline
reduced the severity but not the incidence of acneiform erup-
tion.[7]
In the BOND study,[2] almost 20% of patients treated with
cetuximab never developed acneiform eruption. Using a
preemptive broad-spectrum antibiotic like tetracycline may
thus increase unnecessary consumption and due to our con-
cern about patients’ risk of developing antibiotic resistance,
we decided to examine whether it was possible to avoid or
minimize duration of tetracycline treatment.
To the best of our knowledge, no study has examined nurs-
ing interventions in the management of cetuximab induced
dermatologic toxicity. Previously, our treatment strategy for
dermatologic toxicity was rather coincidental and evaluation
and treatment of acneiform eruption was often not initiated
until moderate or even severe acneiform eruption developed.
Therefore, we performed a pilot study in all patients starting
cetuximab biweekly between April and June 2009 (n = 26).
Patients had GI cancer, and were unselected regarding age
and gender.[8–10] In connection with the first out-patient visit
for cetuximab therapy, patients were educated by the treating
nurse on toxicity of cetuximab with special attention on skin
toxicity including how and when to start tetracycline. In the
pilot study, patients self-administered tetracycline at a dosage
of 333 mg–1,000 mg daily for an indefinite period of time.
Results from the pilot study showed high compliance with
tetracycline and a reduced severity of acneiform eruption.
Therefore we decided to continue with a larger study, with
the objective to confirm results from the pilot study.
2. METHOD
The design was a single group prospective interventional
study executed in a Danish University Hospital at an oncol-
ogy center. The study consisted of nursing management and
patient-education related to acneiform eruption caused by
cetuximab.
2.1 The nursing role
Given that nurses are the interface between the patient and
the physician, we investigated the effect of “early onset”
of treatment with tetracycline, including systematic patient
education by oncology nurses and investigated if this strat-
egy could minimize the severity of acneiform eruption. We
wanted to focus on patients’ resources and capacity to use
their resources available by transferring the onset of treat-
ment from health professional to patient. Thus, the nursing
intervention was inspired by Antonovsky and the philosophy
of salutogenesis,[11] and the concepts of health promotion.[12]
2.2 Patients
All patients with GI cancer treated with cetuximab between
April 2009 and May 2011 were informed and included by
the study nurses. Patients were unselected regarding age and
gender. Medical information was obtained by review of all
individual medical records and included diagnosis, gender
and age.
2.3 Trial interventions
Patients were systematically educated by trained oncology
nurses after the guideline used in the pilot study, consisting of
written information about the study and procedures. Further-
more, patients were by the nurses instructed in precautions
to tetracycline, e.g. dyspeptic genes, skin photosensitivity,
and interaction with dairy products. Dairy products might
inactivate the effect of tetracycline and thus patients were
instructed to avoid dairy products 3 hours before and after
intake of tetracycline. Patients were given 30 pieces of tetra-
cycline 500 mg, to ensure immediately start of treatment in
the patient’s home, at the earliest onset of acneiform eruption.
Patients were also instructed to consult one of three named
nurses by telephone when acneiform eruption appeared. Re-
gardless the grade of acneiform eruption, treatment with
tetracycline 500 mg twice a day for 8 weeks was started.
2.4 Method of evaluation
In the patient record the nurse documented the date of start
and the planned termination date after 8 weeks. In collabo-
ration with dermatologists we prepared a treatment strategy
with recommendations for further treatment in case of severe
skin toxicity e.g. topical medications, cream, lotion, and
other medications was registered. Recommendations could
be used after the nurse or the physician assessment. All
patients were advised on prophylactic skincare with lotion
or cream without alcohol and perfume from the beginning
of treatment. At each visit in the out-clinic for cetuximab
treatment, the patient’s side effects were registered by the
nurse following the data collection tool CTCAE version 3.0.
The American National Cancer Institute (NCI) has developed
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standardized definitions for adverse events – CTCAE (Com-
mon Criteria for adverse events) to describe the severity of
organ toxicity for patients receiving cancer therapy.[13]
2.5 Ethical considerations
Data was collected with the permission of the Danish Data
Protection agency. All patients accepted to participate in the
study, and could withdraw their consent at any time.
2.6 Statistics
Socio-demographic and clinical characteristics of all patients
were described by medians and ranges. Survival was esti-
mated using the Kaplan-Meier method, from time of first
infusion till death or last follow-up date. Data on rash sever-
ity was performed as a landmark analysis only including
patients receiving at least 2 series of cetuximab.
3. RESULTS
3.1 Patient population
Between April 2009 and June 2011, 75 patients started bi-
weekly cetuximab (with chemotherapy) and were enrolled in
the present study. Thirty-eight patients had mCRC[8, 10] and
37 had esophageal or gastric cancer.[9] Sixty-three of these
patients received at least 1 month of therapy with cetuximab,
and were evaluable for intervention analysis. The median
age was 63 years (range 41-77). Thirty-five percent were
female.
3.2 Rash
The median reported time to rash development was 10 days
(95% CI 8-14). Six patients (10%) did not develop any rash
during the study period. Only one patient developed grade 3
skin rash (2%). The remainder (88%) developed grade 1-2
rash. Different grades of acneiform eruption are shown in
Figure 1.
Figure 1. Grades of acneiform eruption according to
CTCAE 3.0
Five patients (8%) had dose reduction of cetuximab due to
dermatologic toxicity. The reported severity of rash did not
differ significantly between gender and age. The severity of
rash per number of cycles given is illustrated in Figure 2.
3.3 Compliance to intervention & therapy
Thirty-nine (62%) of the patients contacted the department
as instructed before initiation of tetracycline. The median
time treated with tetracycline was 56 days (range 5-119).
Twelve patients (19%) needed to resume tetracycline after
the pre-specified 8 week duration. The median time from
planned stop to restart in these patients was 49 days (range
26-100 days).
Patients received a median of 8 (range 3-29) cycles of cetux-
imab. Overall seven patients were dose reduced, five due to
rash and two due to hypomagnesaemia.
3.4 Survival
The median survival for evaluable patients was 13.3 months
(CI 9.5-17.7). Patients with CRC survived longer (17.6
months [CI 13-NR]) than patients with esophageal/gastric
cancer (7.7 months [CI 4.7-11.1]).
Figure 2. The severity of rash
per number of cycles in n = 63
gastro-intestinal cancer patients
treated with cetuximab in
Denmark
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4. DISCUSSION
4.1 Reflections
During this single center prospective study, we systemati-
cally organized the treatment with tetracycline, so only pa-
tients with acneiform eruption started the treatment at the
right moment and for a defined period of time. One aim of
our intervention was to strengthen the patients to be able
to manage their own treatment of acneiform eruption. This
aim succeeded and is in line with Ouwerkerk et al.,[14] who
claimed that oncology nurses can help patients maintain their
quality of life, promoted treatment adherence by empower-
ing patients to be more involved in their treatment and in the
management of treatment-related toxicities.
In the first prophylactic studies, tetracycline was continued
as long as cetuximab was administered. In accordance with
the strategy used by Scope et al.,[7] we decided to limit
the duration of tetracycline therapy to 8 weeks at a dose of
500 mg twice daily.
A lower dose of tetracycline might have the same effect,
but this was not part of the present study and needs to be
investigated in further studies.
In the randomized study by Scope et al.,[7] there was no differ-
ence in severity of skin toxicity after eight weeks of treatment
with cetuximab. These results convinced us not to continue
with tetracycline beyond 8 weeks. However we chose to
continue evaluation of toxicity and evaluate a possible flair
of symptoms which happened in 20% of patients. Those
patients were urged to resume therapy with tetracycline
500 mg twice daily for another four weeks, followed by
a new planned treatment break and re-evaluation.
4.2 Strength
A strength of our study was the prospective design, and the
instant start of tetracycline probably contributed to the low
grade of skin toxicity and helped to maintain full dose inten-
sity without unnecessary delay of cetuximab treatment for
most of the patients. Moreover the need for additional sup-
portive treatment e.g lotion and topical steroids was reduced.
One important aim of our study, was to prevent administra-
tion of unnecessary tetracycline, which succeeded in 10% of
the patients who never developed skin toxicity. We found
that patients who developed acneiform eruption had their first
rash at day 10. This is in contrast to Scope et al., who found
the initial rash between days 14 and 28.[7] In their review
Ouwerkerk et al. found that 80% of the patients developed
acneiform eruption within the first two weeks. Therefore it
is essential for patients to start tetracycline at home, espe-
cially in patients who are being treated with cetuximab every
second week.[14] In relation to development of resistance,
we might question continuation of prophylactic antibiotic
for an indefinite time period. This must be weighed against
treatment with cetuximab in the optimal dose intensity to
secure optimal efficacy. As nurses and oncologist we must
secure optimal treatment, but also avoid unnecessary use
of antibiotics. In our study we found that 10% of patients
never started treatment with tetracycline and additionally
our systematic approach secured, that all patients terminated
prophylactic tetracycline after a planned treatment period.
The major difference between our study and Scope et al.[7]
was that our patients evaluated their own acneiform eruption
and called a named nurse immediately at the time of the first
eruption. This secured an immediate start of tetracycline and
registration of start date.
Around 10%-15% of cetuximab treated patients will develop
grade 3 or 4 skin toxicity without use of prophylactic tetracy-
cline. In our study only one of 63 patients (2%) developed
grade 3 toxicity. In clinical practice (grade 3 or higher) skin
toxicity is a reason for dose reduction or interruption. It is
likely that this might have a negative influence on treatment
outcome. Only 5 patients (8%) in our study had dose re-
duction of cetuximab and no patient discontinued cetuximab
due to skin toxicity. This is much lower than expected from
larger prospective studies.
To have cancer causes loss of control,[15] and with this em-
powering nursing intervention, we believe some of the con-
trol was returned to the patients as the patients expressed they
were well informed and comfortable by starting tetracycline
at home. Furthermore, our guideline provided consensus in
the information to the patients.
4.3 Limitations
Although our study was prospective, one important limitation
was the lack of a control group to understand if our results
were related to our nursing intervention. We did not register
the need for consultation by oncologist before and during the
study, but the nurses are experiencing a decreased demand
for physician consultation. Physicians in our department
recall that they rarely see patients with severe skin toxicity
anymore and they are rarely involved in the handling of skin
toxicity. Also, patients’ behaviors might be changed because
of the relation to a named nurse. They possibly felt more
responsible because of the relation.
The nurses involved were especially trained to evaluate skin
toxicity with CTCAE (version 3.0). Scope et al. used photo
documentation and dermatologist to evaluate the severity of
skin toxicity.[7] In contrast our patients were evaluated by
experienced oncology nurses and only patients with the most
severe eruption were referred to a dermatologist. This new
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approach demands systematic education of oncology nurses,
which may transfer costs between different sections of the
health system.
5. CONCLUSIONS
This prospective nursing intervention study found that
patient-education by a trained oncology nurse in the handling
of cetuximab induced acneiform eruption is manageable and
effective. The systematic approach ensured a high number of
cancer patients carrying through cancer treatment with a full
dose of cetuximab, and spared 10% of the cancer patients
from unnecessary prophylactic tetracycline, and secured, that
all patients terminated after a planned treatment period.
Our guideline was manageable for both patients and nurses.
It resulted in uniformity and experience of security among
physician and nurses, and made the process for patients being
treated with cetuximab more efficient.
Clinical perspectives
The guideline we used for early patient education by nurses
and immediately onset of tetracycline when occurrence of ac-
neiform eruption may be used in other clinical settings. But
it requires trained nurses who will assume the responsibility
of handling the dermatologic toxicity.
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